Get the Stockscreener App
3.20
13.88%
0.39
Gt Biopharma Inc stock is traded at $3.20, with a volume of 651.00K.
It is up +13.88% in the last 24 hours and up +4.58% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$2.81
Open:
$3.03
24h Volume:
651.00K
Relative Volume:
1.86
Market Cap:
$7.15M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-6.9565
EPS:
-0.46
Net Cash Flow:
$-10.11M
1W Performance:
+28.51%
1M Performance:
+4.58%
6M Performance:
+8.84%
1Y Performance:
-59.01%
1-Day Range:
$2.72
$3.39
1-Week Range:
$1.72
$4.10
52-Week Range:
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
315 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.79 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1434 | 302.62M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.72 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.41 | 146.84M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.20 | 54.63M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
New Data Supports BLA Package - Streetwise Reports
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
BeautyHealth Releases 2024 Skintuition Report - Quantisnow
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports
United States Nanobodies Market Size, Trends, Growth, - openPR
Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World
Brokers Set Expectations for GT Biopharma Q4 Earnings - Defense World
Roth Capital Upgrades GT Biopharma (NASDAQ:GTBP) to “Strong-Buy” - Defense World
Is This California Biopharma Co. In the Right Place at the Right Time? - Streetwise Reports
Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports
Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative - Streetwise Reports
GT Biopharma (NASDAQ:GTBP) Now Covered by Analysts at Roth Mkm - Defense World
Roth/MKM bullish on GT Biopharma stock, sees upside from GTB-3650 revenue potential - Investing.com
Nanobodies Market Future Business Opportunities 2024-2031 | - openPR
GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com
GT Biopharma faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GT Biopharma (NASDAQ:GTBP) Enters Investigator Initiated Clinical Trial Agreement with the University of Minnesota - Defense World
GT Biopharma inks clinical trial agreement for cancer treatment - Investing.com
GT Biopharma inks clinical trial agreement for cancer treatment By Investing.com - Investing.com UK
GT Metabolic™ Solutions, Inc., announces completion of the first magnetic compression anastomosis cases in the USA following FDA clearance of its linear magnet technologythe MagDI™ System - Yahoo Finance
GT Biopharma Inc. (GTBP) Quarterly 10-Q Report - Quartzy
GT Biopharma Reports Third Quarter 2024 Financial Results - The Manila Times
GT Biopharma Reports $3.4M Q3 Loss, Advances Key Clinical Trial Timeline | GTBP Stock News - StockTitan
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians - Quantisnow
Nanobodies Market Forecast CAGR 24.1% Projected for Size, Growth, and Share 2024-2031 | Proteintech Group, - EIN News
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):